Long-term follow-up of Hodgkin's disease trial [7]

New England Journal of Medicine

Volumn 346, Issue 18, 2002, Pages 1417-1418

  Canellos, George P ^a   Niedzwiecki, Donna ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; BLEOMYCIN; CHLORMETHINE; DACARBAZINE; DOXORUBICIN; PREDNISONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE;

CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; DRUG INDUCED DISEASE; FOLLOW UP; HODGKIN DISEASE; HUMAN; LETTER; LEUKEMIA; LONG TERM CARE; PRIORITY JOURNAL; SURVIVAL TIME; TREATMENT FAILURE; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE-FREE SURVIVAL; FOLLOW-UP STUDIES; HODGKIN DISEASE; HUMANS; PROPORTIONAL HAZARDS MODELS; RANDOMIZED CONTROLLED TRIALS; SURVIVAL ANALYSIS;

EID: 0037007678     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM200205023461821     Document Type: Letter

References (2)

1. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD
2. Six cycles of ABVD in the treatment of stage I and II Hodgkin's lymphoma: A pilot study